Inventiva S.A.
lanifibranor
metabolic dysfunction-associated steatohepatitis (MASH)
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH) are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“The anticipated Phase 3 top-line readout for lanifibranor in Q4 2026 marks a defining moment for Inventiva.”